Muñoz-Mármol, A.M.; Meléndez, B.; Hernandez, A.; Sanz, C.; Domenech, M.; Arpí-Llucia, O.; Gut, M.; Esteve, A.; Esteve-Codina, A.; Parra, G.;
et al. Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib. Cancers 2025, 17, 375.
https://doi.org/10.3390/cancers17030375
AMA Style
Muñoz-Mármol AM, Meléndez B, Hernandez A, Sanz C, Domenech M, Arpí-Llucia O, Gut M, Esteve A, Esteve-Codina A, Parra G,
et al. Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib. Cancers. 2025; 17(3):375.
https://doi.org/10.3390/cancers17030375
Chicago/Turabian Style
Muñoz-Mármol, Ana Maria, Bárbara Meléndez, Ainhoa Hernandez, Carolina Sanz, Marta Domenech, Oriol Arpí-Llucia, Marta Gut, Anna Esteve, Anna Esteve-Codina, Genis Parra,
and et al. 2025. "Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib" Cancers 17, no. 3: 375.
https://doi.org/10.3390/cancers17030375
APA Style
Muñoz-Mármol, A. M., Meléndez, B., Hernandez, A., Sanz, C., Domenech, M., Arpí-Llucia, O., Gut, M., Esteve, A., Esteve-Codina, A., Parra, G., Carrato, C., Aldecoa, I., Mallo, M., Pineda, E., Alameda, F., de la Iglesia, N., Martinez-Balibrea, E., Martinez-Cardús, A., Estival-Gonzalez, A.,
& Balana, C.
(2025). Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib. Cancers, 17(3), 375.
https://doi.org/10.3390/cancers17030375